Market Outlook
The US Drug Eluting Stent Devices Market is projected to reach approximately USD 7.42 billion by 2035, expanding at a CAGR of 5.6% during the forecast period 2026–2035. The market was valued at an estimated USD 4.31 billion in 2025, with historical analysis covering 2022 to 2024. Growth in this market is primarily driven by the high prevalence of coronary artery disease (CAD), an aging population, increasing percutaneous coronary intervention (PCI) volumes, and technological advancements in polymer coatings and drug delivery mechanisms.
Drug eluting stents (DES) remain the standard of care in the United States for the management of obstructive coronary artery disease. Compared to bare metal stents, DES significantly reduce restenosis rates by releasing antiproliferative drugs that inhibit neointimal hyperplasia. As clinical guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) continue to recommend newer-generation DES for most PCI procedures, adoption remains high across hospitals and specialized cardiac centers.
The US healthcare system’s robust reimbursement structure for interventional cardiology procedures, combined with high awareness levels and strong clinical evidence supporting DES safety and efficacy, continues to create favorable market dynamics. Additionally, the rising incidence of diabetes, obesity, and hypertension in the US population is expanding the patient pool eligible for stent implantation.
Introduction
According to this US Drug Eluting Stent Devices Market report, the industry is shaped by technological innovation, regulatory oversight by the US Food and Drug Administration (FDA), and evolving interventional cardiology practices. Drug eluting stents are minimally invasive devices inserted into narrowed coronary or peripheral arteries to restore blood flow while delivering localized pharmacotherapy.
In the United States, cardiovascular disease remains the leading cause of mortality. The Centers for Disease Control and Prevention (CDC) estimates that nearly 1 in 5 deaths annually are linked to heart disease. As a result, interventional cardiology has become a critical pillar of acute and elective cardiovascular care. Drug eluting stents are now routinely used in cases of stable angina, acute coronary syndromes, and complex multivessel disease.
The market is also influenced by innovation in stent platforms, including thinner strut designs, improved polymer biocompatibility, and bioresorbable scaffolds under investigation. These advancements aim to reduce late stent thrombosis, improve endothelial healing, and shorten dual antiplatelet therapy (DAPT) duration, thereby enhancing patient safety.
Key Market Drivers: What’s Fueling the US Drug Eluting Stent Devices Market Growth?
- Rising Burden of Coronary Artery Disease and Lifestyle Disorders
The growing prevalence of coronary artery disease is the single most important driver of DES demand in the United States. Sedentary lifestyles, poor dietary habits, smoking, and metabolic disorders such as diabetes contribute significantly to atherosclerosis. The increasing number of patients undergoing PCI procedures directly translates to higher stent volumes.
With over one million PCI procedures performed annually in the US, drug eluting stents account for the majority of implanted stents. The strong clinical preference for DES over bare metal stents due to lower revascularization rates supports sustained demand. - Technological Advancements in Stent Design
Innovation in stent engineering continues to drive market growth. Second- and third-generation DES utilize cobalt chromium and platinum chromium alloys with ultra-thin struts, enhancing flexibility and deliverability in tortuous vessels. Improved polymer technologies allow for controlled drug release kinetics and reduced inflammatory response. - Bioresorbable polymer DES are gaining attention for minimizing long-term polymer exposure, potentially reducing late adverse events. These design improvements are encouraging cardiologists to use DES even in complex lesions, chronic total occlusions, and high-risk diabetic populations.
- Favorable Reimbursement and Established Clinical Guidelines
In the US, Medicare and private insurers provide reimbursement for PCI procedures, including DES implantation. The established reimbursement framework ensures procedural accessibility and financial viability for healthcare providers.
Additionally, ACC/AHA guidelines strongly recommend newer-generation DES for most clinical scenarios. This endorsement reinforces physician confidence and standardizes DES usage across healthcare facilities.
Innovation in Focus: How Manufacturers Are Advancing Drug Eluting Stent Technologies?
Manufacturers in the US are focusing on improving safety profiles, reducing stent thrombosis rates, and enhancing long-term vessel healing. Innovations include biodegradable polymer coatings that dissolve after drug release, minimizing chronic inflammation.
Next-generation DES platforms emphasize ultrathin struts, improving flexibility and conformability in complex anatomies. Research is also exploring polymer-free stents and dual-drug elution systems to further optimize antiproliferative efficacy.
Digital integration in catheterization labs, including imaging guidance with intravascular ultrasound (IVUS) and optical coherence tomography (OCT), is enhancing stent placement precision. These complementary technologies indirectly support DES market growth by improving procedural outcomes.
Recent Developments
Recent years have seen growing adoption of ultrathin strut DES and bioresorbable polymer technologies. Clinical trials in the US continue to evaluate shorter DAPT regimens supported by newer-generation DES safety data.
Strategic collaborations between device manufacturers and hospital systems are increasing to optimize supply chains and improve procedural efficiency. Additionally, digital cath lab integration with advanced imaging guidance systems enhances procedural accuracy and stent optimization.
Conclusion
The US Drug Eluting Stent Devices Market Size & Share is poised for stable growth through 2035, supported by rising cardiovascular disease prevalence, technological advancements, and strong reimbursement frameworks. Drug eluting stents remain the gold standard in PCI procedures across the United States.
With continued innovation in materials, drug coatings, and stent architecture, the market is expected to maintain steady expansion while enhancing patient outcomes and procedural safety. Regional disparities in disease burden and healthcare infrastructure will continue to shape state-level growth patterns, making the US DES market both dynamic and strategically significant within the broader cardiovascular device industry.
Key Market Players
The US Drug Eluting Stent Devices Market is moderately consolidated, with multinational corporations and specialized cardiovascular device manufacturers competing on innovation and clinical performance.
- Abbott Laboratories maintains a strong presence with its Xience family of everolimus-eluting stents widely used in US hospitals.
- Boston Scientific Corporation offers the SYNERGY stent platform, known for its bioabsorbable polymer design and strong adoption across US cath labs.
- Medtronic provides the Resolute series, a widely implanted zotarolimus-eluting stent platform in the US.
- Terumo Corporation has expanded its US footprint through advanced coronary intervention devices.
- Biotronik delivers ultrathin strut DES platforms tailored for complex coronary anatomies.
- B. Braun Melsungen AG participates through vascular intervention solutions in select US markets.
- MicroPort Scientific Corporation is gradually expanding US distribution partnerships.
- Cook Medical offers peripheral intervention solutions relevant to DES applications.
- Meril Life Sciences is entering competitive segments with advanced DES technologies.
- Amaranth Medical has focused on bioresorbable scaffold innovation.
- Reva Medical has worked on bioresorbable vascular scaffolds targeting US trials.
- Elixir Medical develops novel DES platforms emphasizing polymer-free technologies.
- OrbusNeich provides stent solutions with increasing US penetration.
- Lepu Medical Technology collaborates with US distributors for select product lines.
- Cardinal Health plays a distribution and supply chain role in cardiovascular devices.
- Teleflex Incorporated supports interventional cardiology product portfolios.
- Stryker Corporation participates in peripheral vascular solutions.
- Philips Healthcare supports imaging systems critical for DES placement.
- Siemens Healthineers enhances cath lab imaging integration.
- GE HealthCare provides interventional imaging technologies supporting stent deployment.
- Coronary Drug Eluting Stents (Dominant Segment)
Coronary DES account for the largest market share in the United States. These stents are used primarily in PCI procedures for treating obstructive coronary artery disease. High procedural volumes in tertiary care hospitals and cardiac specialty centers sustain demand.
Complex PCI cases, including bifurcation lesions and multivessel interventions, increasingly utilize advanced coronary DES platforms with enhanced radial strength and deliverability. - Peripheral Drug Eluting Stents (Growing Segment)
Peripheral DES are used in peripheral artery disease (PAD), particularly in femoropopliteal and below-the-knee arteries. Rising PAD prevalence among diabetic and elderly populations is contributing to segment expansion.
Although smaller than coronary DES, this segment is witnessing increasing adoption as minimally invasive vascular interventions gain popularity.
- Everolimus-Based Stents (Dominant)
Everolimus-eluting stents hold a leading market share due to strong clinical evidence supporting reduced restenosis and thrombosis rates. These stents are widely adopted in US catheterization labs. - Sirolimus-Based Stents
Sirolimus-based DES remain important, especially in newer-generation bioresorbable polymer designs. They are recognized for their effective inhibition of smooth muscle proliferation. - Zotarolimus-Based Stents
Zotarolimus-based platforms are favored for rapid endothelialization and reduced late complications. These stents are widely used in both elective and emergency PCI cases. - Paclitaxel-Based Stents
Paclitaxel-based DES have seen limited use in coronary applications but maintain relevance in certain peripheral interventions. - Others
Emerging drug platforms and combination therapies are under clinical investigation to improve long-term safety and efficacy outcomes.
- Hospitals (Dominant Segment)
Large hospitals perform the majority of PCI procedures in the United States. Advanced catheterization labs, availability of cardiac surgery backup, and high patient inflow contribute to segment dominance. - Cardiac Catheterization Laboratories
Standalone cath labs and heart institutes represent a significant share, especially in urban and suburban regions. These facilities focus on high-volume interventional procedures. - Ambulatory Surgical Centers (Growing Segment)
Ambulatory centers are gradually expanding into select cardiovascular interventions. While still limited in complex PCI, outpatient DES implantation is expected to increase as minimally invasive techniques evolve.
- Cobalt Chromium (Dominant)
Cobalt chromium alloys are widely used due to high radial strength and thinner strut capability. This material enhances flexibility and reduces restenosis risk. - Platinum Chromium
Platinum chromium offers superior radiopacity, aiding precise placement under fluoroscopy. It is increasingly used in complex coronary anatomies. - Stainless Steel
Although less common in modern DES, stainless steel platforms are still utilized in certain cost-sensitive applications. - Biodegradable Polymers
Biodegradable polymer DES are gaining attention for reducing long-term inflammatory response and improving vessel healing.
West (Leading Region)
The West region, including California, Washington, Arizona, Colorado, Oregon, and others, leads in DES adoption. California alone accounts for a significant share due to its large population and high concentration of advanced cardiac centers such as those in Los Angeles, San Francisco, and San Diego.
The region benefits from strong academic institutions, early technology adoption, and advanced catheterization labs. High healthcare spending per capita supports rapid integration of next-generation DES technologies.
Northeast
The Northeast, including New York, Massachusetts, Pennsylvania, and New Jersey, shows high procedural density due to established academic medical centers. Hospitals in Boston and New York City are recognized leaders in interventional cardiology research.
An aging population in this region increases PCI volumes, sustaining DES demand. Research collaborations and clinical trials are particularly active here.
South (Fastest Growing)
The South region, including Texas, Florida, Georgia, and North Carolina, is witnessing rapid growth. High cardiovascular disease prevalence, driven by obesity and diabetes rates, significantly increases intervention volumes.
Texas and Florida represent large patient pools and expanding hospital networks. Modernization of healthcare facilities and population growth are accelerating DES demand.
Midwest
The Midwest, including Illinois, Ohio, Michigan, and Minnesota, shows steady growth. Large integrated health systems and emphasis on value-based care influence purchasing decisions.
Urban centers such as Chicago and Cleveland serve as major hubs for interventional cardiology procedures.
1. US Drug Eluting Stent Devices Market: Market Introduction & Context
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Methodology
1.3.1 Primary Data Collection
1.3.2 Secondary Data Sourcing
1.3.3 External Industry Collaborations
1.3.4 In-House Research Databases
1.3.5 Analytical Frameworks & Forecasting Models
1.3.6 Data Validation and Final Report Publishing
1.4 Key Assumptions
1.5 Market Ecosystem Overview
1.6 Stakeholder Analysis
What this section provides:
Introduces definitions, scope, methodology, assumptions, ecosystem mapping, and research validation framework.
2. US Drug Eluting Stent Devices Market: Executive Summary
2.1 Key Insights & Market Snapshot
2.2 Market Size & Forecast Overview (2022–2035)
2.3 Analyst Viewpoint
2.4 Market Attractiveness Index
2.5 Strategic Imperatives
What this section provides:
Provides a concise overview of market size, CAGR, key trends, and strategic highlights.
3. US Drug Eluting Stent Devices Market: Market Dynamics & Outlook
3.1 Market Drivers
3.1.1 Rising Coronary Artery Disease Prevalence
3.1.2 Increasing PCI Procedure Volumes
3.1.3 Favorable Reimbursement Structure
3.1.4 Technological Advancements in DES
3.2 Market Restraints
3.2.1 Pricing Pressures
3.2.2 Risk of Late Stent Thrombosis
3.2.3 Regulatory Challenges
3.3 Market Opportunities
3.3.1 Bioresorbable & Polymer-Free Platforms
3.3.2 Peripheral Indication Expansion
3.3.3 Shortened DAPT Regimens
3.4 Patent & Innovation Analysis (2020–2025)
What this section provides:
Explains growth drivers, restraints, innovation landscape, and future opportunities.
4. US Drug Eluting Stent Devices Market: Market Environment & Industry Analysis
4.1 PESTEL Analysis
4.1.1 Political
4.1.2 Economic
4.1.3 Social
4.1.4 Technological
4.1.5 Environmental
4.1.6 Legal
4.2 Porter’s Five Forces Analysis
4.2.1 Threat of New Entrants
4.2.2 Bargaining Power of Buyers
4.2.3 Bargaining Power of Suppliers
4.2.4 Threat of Substitutes
4.2.5 Competitive Rivalry
4.3 Pricing Trend Analysis (2024–2030)
4.4 Value Chain & Supply Chain Analysis
4.5 Regulatory Framework Analysis
4.6 Import/Export & Tariff Impact
4.7 Government Initiatives
4.8 Impact of Geopolitical Tensions
What this section provides:
Delivers macroeconomic, competitive, regulatory, and supply chain insights.
5. US Drug Eluting Stent Devices Market – By Product Type
5.1 Overview
5.2 Segment Share Analysis, 2025 & 2035 (%)
5.3 Coronary Drug Eluting Stents
5.4 Peripheral Drug Eluting Stents
What this section provides:
Breaks down revenue distribution between coronary and peripheral DES segments.
6. US Drug Eluting Stent Devices Market – By Drug Type
6.1 Overview
6.2 Segment Share Analysis, 2025 & 2035 (%)
6.3 Everolimus-Based
6.4 Sirolimus-Based
6.5 Zotarolimus-Based
6.6 Paclitaxel-Based
6.7 Others
What this section provides:
Analyzes drug technology preferences and clinical adoption trends.
7. US Drug Eluting Stent Devices Market – By Material
7.1 Overview
7.2 Segment Share Analysis, 2025 & 2035 (%)
7.3 Cobalt Chromium
7.4 Platinum Chromium
7.5 Stainless Steel
7.6 Biodegradable Polymer Platforms
What this section provides:
Examines material innovations driving performance and physician preference.
8. US Drug Eluting Stent Devices Market – By End-User
8.1 Overview
8.2 Segment Share Analysis, 2025 & 2035 (%)
8.3 Hospitals
8.4 Cardiac Catheterization Laboratories
8.5 Ambulatory Surgical Centers
What this section provides:
Identifies demand concentration across healthcare facilities.
9. US Drug Eluting Stent Devices Market – By Geography
9.1 Introduction
9.2 Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.3 West Region
9.3.1 Regional Overview & Trends
9.3.2 Market Size & Forecast (2025–2035)
9.3.3 By Product Type
9.3.4 By Drug Type
9.3.5 By Material
9.3.6 By End-User
9.3.7 California
9.3.8 Washington
9.3.9 Colorado
9.3.10 Arizona
9.3.11 Oregon
9.3.12 Others
9.3.12.1 Utah
9.3.12.2 Nevada
9.3.12.3 New Mexico
9.3.12.4 Idaho
9.3.12.5 Montana
9.3.12.6 Wyoming
9.3.12.7 Alaska
9.3.12.8 Hawaii
9.4 Northeast Region
9.4.1 Regional Overview & Trends
9.4.2 New York
9.4.3 Massachusetts
9.4.4 New Jersey
9.4.5 Pennsylvania
9.4.6 Connecticut
9.4.7 Others
9.4.7.1 Maine
9.4.7.2 Vermont
9.4.7.3 New Hampshire
9.4.7.4 Rhode Island
9.4.7.5 Delaware
9.5 South Region
9.5.1 Regional Overview & Trends
9.5.2 Texas
9.5.3 Florida
9.5.4 Georgia
9.5.5 North Carolina
9.5.6 Tennessee
9.5.7 South Carolina
9.5.8 Alabama
9.5.9 Others
9.5.9.1 Mississippi
9.5.9.2 Louisiana
9.5.9.3 Arkansas
9.5.9.4 Kentucky
9.5.9.5 Oklahoma
9.5.9.6 Virginia
9.5.9.7 Maryland
9.5.9.8 West Virginia
9.6 Midwest Region
9.6.1 Regional Overview & Trends
9.6.2 Illinois
9.6.3 Ohio
9.6.4 Michigan
9.6.5 Minnesota
9.6.6 Indiana
9.6.7 Wisconsin
9.6.8 Missouri
9.6.9 Others
9.6.9.1 Iowa
9.6.9.2 Kansas
9.6.9.3 Nebraska
9.6.9.4 North Dakota
9.6.9.5 South Dakota
What this section provides:
Delivers comprehensive regional and state-level revenue forecasts and growth hotspot identification.
10. US Drug Eluting Stent Devices Market: Competitive Landscape & Company Profiles
10.1 Market Share Analysis (2025)
10.2 Company Positioning Matrix
10.3 Company Profiles
10.3.1 Abbott Laboratories
10.3.2 Boston Scientific Corporation
10.3.3 Medtronic plc
10.3.4 Terumo Corporation
10.3.5 Biotronik SE & Co. KG
10.3.6 B. Braun Melsungen AG
10.3.7 MicroPort Scientific Corporation
10.3.8 Cook Medical
10.3.9 Meril Life Sciences Pvt. Ltd.
10.3.10 Elixir Medical Corporation
10.3.11 OrbusNeich Medical Group
10.3.12 Lepu Medical Technology
10.3.13 Reva Medical, Inc.
10.3.14 Amaranth Medical
10.3.15 Cardinal Health
10.3.16 Teleflex Incorporated
10.3.17 Stryker Corporation
10.3.18 Philips Healthcare
10.3.19 Siemens Healthineers
10.3.20 GE HealthCare
What this section provides:
Competitive benchmarking, market share positioning, and strategic company analysis.
11. US Drug Eluting Stent Devices Market: Future Market Outlook (2025–2035)
11.1 Scenario Analysis
11.2 Emerging Technologies Impact
11.3 Investment Opportunities
11.4 Strategic Roadmap
What this section provides:
Forecast outlook, future growth modeling, and investment planning insights.
12. US Drug Eluting Stent Devices Market: Strategic Recommendations
12.1 For Manufacturers
12.2 For Investors
12.3 For Healthcare Providers
12.4 For New Entrants
What this section provides:
Actionable recommendations for maximizing market share and profitability.
13. US Drug Eluting Stent Devices Market: Disclaimer
13.1 Legal Disclaimer
13.2 Data Limitations
13.3 Intellectual Property Notice
What this section provides:
Clarifies usage terms and report limitations.
List of Tables
TABLE 1: List of Data Sources
TABLE 2: Market Drivers; Impact Analysis
TABLE 3: Market Restraints; Impact Analysis
TABLE 4: US Drug Eluting Stent Devices Market: Product Type Snapshot (2025)
TABLE 5: Segment Dashboard; Definition and Scope, by Product Type
TABLE 6: US Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 7: US Drug Eluting Stent Devices Market: Drug Type Snapshot (2025)
TABLE 8: Segment Dashboard; Definition and Scope, by Drug Type
TABLE 9: US Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 10: US Drug Eluting Stent Devices Market: Material Snapshot (2025)
TABLE 11: Segment Dashboard; Definition and Scope, by Material
TABLE 12: US Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 13: US Drug Eluting Stent Devices Market: End-User Snapshot (2025)
TABLE 14: Segment Dashboard; Definition and Scope, by End-User
TABLE 15: US Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 16: US Drug Eluting Stent Devices Market: Regional Snapshot (2025)
TABLE 17: Segment Dashboard; Definition and Scope, by Region
TABLE 18: US Drug Eluting Stent Devices Market, by Region, 2022–2035 (USD Million)
TABLE 19: California Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 20: California Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 21: California Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 22: California Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 23: Washington Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 24: Washington Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 25: Washington Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 26: Washington Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 27: Colorado Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 28: Colorado Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 29: Colorado Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 30: Colorado Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 31: Arizona Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 32: Arizona Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 33: Arizona Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 34: Arizona Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 35: Oregon Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 36: Oregon Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 37: Oregon Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 38: Oregon Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 39: West – Others Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 40: West – Others Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 41: West – Others Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 42: West – Others Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
(Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, Hawaii)
TABLE 43: New York Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 44: New York Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 45: New York Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 46: New York Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 47: Massachusetts Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 48: Massachusetts Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 49: Massachusetts Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 50: Massachusetts Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 51: New Jersey Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 52: New Jersey Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 53: New Jersey Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 54: New Jersey Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 55: Pennsylvania Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 56: Pennsylvania Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 57: Pennsylvania Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 58: Pennsylvania Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 59: Connecticut Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 60: Connecticut Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 61: Connecticut Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 62: Connecticut Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 63: Northeast – Others Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 64: Northeast – Others Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 65: Northeast – Others Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 66: Northeast – Others Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
(Maine, Vermont, New Hampshire, Rhode Island, Delaware)
TABLE 67: Texas Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 68: Texas Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 69: Texas Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 70: Texas Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 71: Florida Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 72: Florida Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 73: Florida Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 74: Florida Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 75: Georgia Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 76: Georgia Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 77: Georgia Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 78: Georgia Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 79: North Carolina Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 80: North Carolina Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 81: North Carolina Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 82: North Carolina Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 83: Tennessee Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 84: Tennessee Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 85: Tennessee Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 86: Tennessee Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 87: South Carolina Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 88: South Carolina Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 89: South Carolina Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 90: South Carolina Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 91: Alabama Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 92: Alabama Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 93: Alabama Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 94: Alabama Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 95: South – Others Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 96: South – Others Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 97: South – Others Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 98: South – Others Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
(Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland, West Virginia)
TABLE 99: Illinois Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 100: Illinois Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 101: Illinois Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 102: Illinois Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 103: Ohio Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 104: Ohio Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 105: Ohio Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 106: Ohio Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 107: Michigan Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 108: Michigan Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 109: Michigan Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 110: Michigan Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 111: Minnesota Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 112: Minnesota Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 113: Minnesota Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 114: Minnesota Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 115: Indiana Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 116: Indiana Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 117: Indiana Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 118: Indiana Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 119: Wisconsin Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 120: Wisconsin Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 121: Wisconsin Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 122: Wisconsin Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 123: Missouri Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 124: Missouri Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 125: Missouri Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 126: Missouri Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
TABLE 127: Midwest – Others Drug Eluting Stent Devices Market, by Product Type, 2022–2035 (USD Million)
TABLE 128: Midwest – Others Drug Eluting Stent Devices Market, by Drug Type, 2022–2035 (USD Million)
TABLE 129: Midwest – Others Drug Eluting Stent Devices Market, by Material, 2022–2035 (USD Million)
TABLE 130: Midwest – Others Drug Eluting Stent Devices Market, by End-User, 2022–2035 (USD Million)
(Iowa, Kansas, Nebraska, North Dakota, South Dakota)
List of Figures
FIGURE 1: US Drug Eluting Stent Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: PESTEL Analysis
FIGURE 5: Porter’s Five Forces Analysis
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: Market Dynamics
FIGURE 8: Innovation & Patent Landscape (2020–2025)
FIGURE 9: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 10: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 11: Product Type Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 12: Drug Type Segment Market Share Analysis, 2025 & 2035
FIGURE 13: Drug Type Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 14: Material Segment Market Share Analysis, 2025 & 2035
FIGURE 15: Material Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 16: End-User Segment Market Share Analysis, 2025 & 2035
FIGURE 17: End-User Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 18: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Regional Segment Market Size Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 20: West Region US Drug Eluting Stent Devices Market Share and Leading Players, 2025
FIGURE 21: Northeast Region US Drug Eluting Stent Devices Market Share and Leading Players, 2025
FIGURE 22: South Region US Drug Eluting Stent Devices Market Share and Leading Players, 2025
FIGURE 23: Midwest Region US Drug Eluting Stent Devices Market Share and Leading Players, 2025
FIGURE 24: West Region Market Share Analysis by State, 2025
FIGURE 25: California Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 26: Washington Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 27: Colorado Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 28: Arizona Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 29: Oregon Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 30: Others (West Region) Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 31: South Region Market Share Analysis by State, 2025
FIGURE 32: Texas Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 33: Florida Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 34: Georgia Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 35: North Carolina Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 36: Tennessee Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 37: South Carolina Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 38: Alabama Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 39: Others (South Region) Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 40: Midwest Region Market Share Analysis by State, 2025
FIGURE 41: Illinois Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 42: Ohio Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 43: Michigan Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 44: Minnesota Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 45: Indiana Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 46: Wisconsin Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 47: Missouri Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 48: Others (Midwest Region) Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 49: Northeast Region Market Share Analysis by State, 2025
FIGURE 50: New York Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 51: Massachusetts Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 52: New Jersey Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 53: Pennsylvania Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 54: Connecticut Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
FIGURE 55: Others (Northeast Region) Drug Eluting Stent Devices Market Size, Forecast and Trend Analysis, 2025–2035 (USD Million)
